Advertisement
Advertisement

HIV Care Today


HIV Incidence: The Latest Numbers
By Paul E. Sax, M.D.
January 1, 2013

The CDC has recently issued the latest report on HIV incidence (i.e., new infections) in the United States, and as always it's fascinating to review the numbers.

Read more …


The U.S. Preventive Services Task Force Recommends HIV Screening -- And Why Is This News?
By Paul E. Sax, M.D.
November 22, 2012

A flurry of coverage recently appeared about the U.S. Preventive Services Task Force's recommendation for one-time HIV screening for all Americans, ages 15-64.

Some might wonder why this is news -- um, hasn't this been recommended now for years? -- and I think I've figured it out.

Read more …


The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors
By Paul E. Sax, M.D.
November 18, 2012

The FDA has approved an 800-mg tablet of darunavir for treatment naive patients. This single tablet will obviously replace the two darunavir 400-mg tablets in first-line therapy. (Yes, my math is that good.) Darunavir will still require 100-mg ritonavir boosting plus two NRTIs to make a complete regimen.

Read more …


Vitamins and the Department of Bad Timing
By Paul E. Sax, M.D.
November 7, 2012

Now that the election is over, we can get back to something that really matters -- namely vitamins, and specifically whether they really help people.

Read more …


Antiretroviral Rounds: Resistance on Two Fronts
By Paul E. Sax, M.D.
November 2, 2012

Got this challenging curbside consult from a colleague, and it has an interesting wrinkle.

Read more …


Dolutegravir and the 88 Percent Rule
By Paul E. Sax, M.D.
October 28, 2012

In the latest treatment-naive trials of elvitegravir and dolutegravir, there's a striking consistency in the results of the "test" regimen. Here are the studies, with the percentage of responders by treatment arm ...

Read more …


Can a "Treat Everyone With HIV" Policy Actually Work? In San Francisco, Yes
By Paul E. Sax, M.D.
October 22, 2012

As has often been the case in the history of the HIV epidemic, the HIV/AIDS Division at San Francisco General Hospital and the San Francisco Department of Health were ahead of the curve in 2010 when they issued a recommendation that all people with HIV should receive treatment, regardless of CD4 count. Of course, U.S. guidelines (first DHHS, now IAS-USA) followed suit -- but how did the San Francisco experience play out?

Read more …


It's Time to Tell Our Patients to Stop Their Vitamin Supplements
By Paul E. Sax, M.D.
October 17, 2012

Over in JAMA, there's a large study out today that (yet again) failed to demonstrate a benefit of vitamins.

Read more …


It's Time to Dump the HIV Western Blot
By Paul E. Sax, M.D.
September 19, 2012

Hard to believe, but we have to get rid of the HIV Western blot -- at least as our HIV confirmatory test.

Read more …


Thoughts on "Quad" Approval by FDA
By Paul E. Sax, M.D.
August 28, 2012

We now have a third single-pill treatment available for HIV treatment, co-formulated tenofovir/emtricitabine/elvitegravir/cobicistat. From the FDA announcement:

The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection. Stribild contains two previously approved HIV drugs plus two new drugs, elvitegravir and cobicistat ... Together, these drugs provide a complete treatment regimen for HIV infection.

Read more …

 < Prev  |  1  |  …  |  4  |  5  |  6  |  7  |  8  |  …  |  15  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement